Navigation Links
Misleading anti-malarial drug

Promotional claims about the preventive efficacy of a malaria drug are being questioned by experts, who say the statements are misleading and should be withdrawn. Manufacturer GlaxoSmithKline markets the anti-malarial drug Malarone (atovaquone and proguanil) as being 97 per cent effective at preventing the aggressive falciparum strain of malaria, but the Drug and Therapeutics Bulletin (DTB) – published by the Consumers’ Association – says the evidence for this is misleading. //

DTB says that no study has been published into the drug’s effectiveness as a malaria preventative in non-immune populations from countries such as the UK where the disease is not endemic. The publication warns that it is not known if Malarone is as effective as the previous main choices – mefloquine and doxycycline.

Professor Joe Collier, editor of Drug and Therapeutics Bulletin, said the lack of published evidence in non-immune travellers meant there was nothing to support the manufacturer’s promotional claim about Malarone’s effectiveness and that the claim should be withdrawn as a result. A spokesperson for GlaxoSmithKline said the company supported the 97 per cent efficacy rate indicated by the three efficacy trials carried out in Africa.
>
'"/>




Page: 1

Related medicine news :

1. Misleading Advertisements for Prescription Drugs
2. The Effects Of Smoking Misleading
3. Lifting The Screen off Misleading Sunscreen labels
4. Misleading Health Claims On Food Labels No Longer Allowed in EU
5. Walkers Crisps Advertisements make Misleading Claims about Salt Content
6. Medical Council Of India Draws Public Attention on Misleading Ads.
7. Obesity Drug Advertisements Misleading Teens
8. Labeling of Dairy Products with Trans fat labels, Misleading to Consumers
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Misleading anti malarial drug

(Date:7/24/2014)... Exposure to light at night, which shuts off nighttime ... resistant to tamoxifen, a widely used breast cancer drug, ... Medicine cancer researchers. The study, "Circadian and Melatonin Disruption ... to Tamoxifen Therapy in Breast Cancer," published in the ... show that melatonin is vital to the success of ...
(Date:7/24/2014)... 24, 2014 Vulnerable populations such ... households are disproportionately affected by food security, despite ... in the United States, according to a new ... of the Consolidated Appropriations Act, 2014 (P.L. 113-76), ... and Nutrition Service (FNS) to contract with a ...
(Date:7/24/2014)... 2014 Just as fitness and health ... their own financial and marketing strength to be important ... to the next level by using the most powerful ... Voice Broadcast, Call Tracking and SMS texting solutions ... text messages are quickly become integral in marketing and ...
(Date:7/24/2014)... NJ (PRWEB) July 24, 2014 ... leading specialist in hematology and oncology, Dr. Hitendra ... Group. Our system welcomes Dr. Upadhyaya to the ... comprise CarePoint Health Medical Group, a comprehensive network ... representing a wide range of specialties. This latest ...
(Date:7/24/2014)... found a way to delay or even prevent Alzheimer,s ... the anti-aging protein Klotho can prevent neuron death in ... These findings currently appear in the Journal of ... most frequent age-related dementia affecting 5.4 million Americans including ... more than 40 percent of people over the age ...
Breaking Medicine News(10 mins):Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:Report: Vulnerable Populations Disproportionately Affected by Food Security, Despite Public Programs 2Health News:Report: Vulnerable Populations Disproportionately Affected by Food Security, Despite Public Programs 3Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 2Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 3Health News:Dr. Upadhyaya Joins CarePoint Health Medical Group 2Health News:BU researchers discover that Klotho is neuroprotective against Alzheimer's disease 2
... AMERIGROUP Corporation (NYSE: AGP ) today announced ... Healthcare Conference on May 18 in Boston.A live broadcast of ... Eastern Time, can be accessed on AMERIGROUP,s Web site, ... will be available for 30 days, and can be accessed ...
... could cut the death risk in half, study finds, , , ... just help others; it turns out, it probably benefits your ... less than half the risk of dying compared to their ... the American Geriatrics Society annual meeting, in Chicago. , ...
... May 8 The federal government has made tax ... companies with the implementation of simple automation into new ... incentives will have a positive impact on organizations purchasing ... while providing increased efficiencies and a high internal rate ...
... 8 Valeant Pharmaceuticals International (NYSE: VRX ... privately held company located in Poland for approximately $28 ... in Poland into multiple therapeutic categories. EMO-FARM has a ... a portfolio of currently marketed products and additional products ...
... JLL Partners, Inc. and its affiliate, JLL Patheon Holdings, ... (Toronto time) on May 7, 2009 (the "Expiry Time") 31,411,927 ... were validly deposited to JLL,s offer to acquire, at a ... the issued and outstanding Restricted Voting Shares of Patheon (the ...
... In the 25 years between 1981 and 2006 mortality rates ... remarkable 80% in men and women aged between 25 and ... Were the health services of Iceland so much better, or ... Dr Thor Aspelund and colleagues from the Icelandic Heart Association ...
Cached Medicine News:Health News:Seniors Who Volunteer May Live Longer 2Health News:Seniors Who Volunteer May Live Longer 3Health News:Valeant to Acquire Polish Dermatology Company 2Health News:JLL Announces Extension of Its Offer To Acquire Patheon and Take Up of Deposited Restricted Voting Shares 2Health News:JLL Announces Extension of Its Offer To Acquire Patheon and Take Up of Deposited Restricted Voting Shares 3Health News:Massive decline in rates of coronary death in Iceland are largely attributed to risk factor reductions in the population 2
(Date:7/24/2014)... CAMPBELL, Calif. , July 24, 2014 /PRNewswire/ ... the development of novel interventional devices to facilitate ... United States Patent and Trademark Office has issued ... core technology behind the company,s Lazarus Cover TM ... The Lazarus ReCover is a single-component stent-retriever ...
(Date:7/24/2014)... -- In any given hospital in the country at any ... one hospital-acquired infection, according to the Centers of Disease ... prove fatal. And as increased surveillance has shown that ... per year, infection control efforts have drifted to the ... stronger emphasis is being placed upon innovative and comprehensive ...
(Date:7/24/2014)... ANAHEIM, Calif., July 24, 2014 Questcor Pharmaceuticals, Inc. ... the second quarter ended June 30, 2014. Three Months Ended ... $278.8 Million , $184.6 Million , 51% Non-GAAP Net ... GAAP Diluted EPS , $1.54 , $1.12 ... , $1.35 , 37%  Six Months ...
Breaking Medicine Technology:Lazarus Effect Receives Notice of Allowance for New US Patent Covering Core Protection Technology 2Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 2Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 3Questcor Reports Record Second Quarter Financial Results 2Questcor Reports Record Second Quarter Financial Results 3Questcor Reports Record Second Quarter Financial Results 4Questcor Reports Record Second Quarter Financial Results 5Questcor Reports Record Second Quarter Financial Results 6Questcor Reports Record Second Quarter Financial Results 7Questcor Reports Record Second Quarter Financial Results 8Questcor Reports Record Second Quarter Financial Results 9Questcor Reports Record Second Quarter Financial Results 10Questcor Reports Record Second Quarter Financial Results 11Questcor Reports Record Second Quarter Financial Results 12Questcor Reports Record Second Quarter Financial Results 13Questcor Reports Record Second Quarter Financial Results 14Questcor Reports Record Second Quarter Financial Results 15Questcor Reports Record Second Quarter Financial Results 16Questcor Reports Record Second Quarter Financial Results 17Questcor Reports Record Second Quarter Financial Results 18Questcor Reports Record Second Quarter Financial Results 19Questcor Reports Record Second Quarter Financial Results 20Questcor Reports Record Second Quarter Financial Results 21Questcor Reports Record Second Quarter Financial Results 22Questcor Reports Record Second Quarter Financial Results 23Questcor Reports Record Second Quarter Financial Results 24Questcor Reports Record Second Quarter Financial Results 25Questcor Reports Record Second Quarter Financial Results 26Questcor Reports Record Second Quarter Financial Results 27Questcor Reports Record Second Quarter Financial Results 28
... the detailed information you need to make ... with palpitations, syncope and intermittent chest pain., ... this transtelephonic cardiac event monitor requires just ... ECG. Comfortable for your patients to wear ...
... The MULTIVIEW WORKSTATION enhances patient care ... rapid assessment, decision support, and clinical ... Part of the INFINITY Patient Monitoring ... patient information, including continuous, real-time patient ...
... offers the ultimate PET/CT performance ... treatment in oncology, neurology, and ... whole body scans in less ... suite of clinical applications offers ...
... SOMATOM Sensation is the highly respected single-source ... branches to visualizing plaque. With its proprietary ... fastest rotation time of 0.33s, virtually freezing ... Technology, the system delivers unprecedented diagnostic detail ...
Medicine Products: